Blarcamesine

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (April 2018) (Learn how and when to remove this message) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Blarcamesine" – news · newspapers · books · scholar · JSTOR (September 2017) (Learn how and when to remove this message) (Learn how and when to remove this message)

Blarcamesine

Clinical data
Other names	ANAVEX 2-73
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name 1-(2,2-Diphenyltetrahydro-3-furanyl)-N,N-dimethylmethanamine
CAS Number	195615-83-9
PubChem CID	9882189
DrugBank	DB05592
ChemSpider	8057864
UNII	9T210MMZ3F
KEGG	D11383
ChEMBL	ChEMBL4297224
CompTox Dashboard (EPA)	DTXSID60941344
Chemical and physical data
Formula	C19H23NO
Molar mass	281.399 g·mol−1
3D model (JSmol)	Interactive image
SMILES O3C(c1ccccc1)(c2ccccc2)C(CN(C)C)CC3
InChI InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3 Key:BOTHKNZTGGXFEQ-UHFFFAOYSA-N

Blarcamesine (developmental code name ANAVEX 2-73) is an experimental drug which is under development for the treatment of Alzheimer's disease and a variety of other indications.^[1]

Blarcamesine acts as an agonist of the sigma σ₁ receptor, the muscarinic acetylcholine M₁ receptor, and the ionotropic glutamate NMDA receptor.^[2][1]

The drug was developed by Anavex Life Sciences.^[1] As of August 2024, it is in preregistration for Alzheimer's disease, phase 2/3 clinical trials for fragile X syndrome and Rett syndrome, phase 2 trials for Parkinson's disease, and phase 1 trials for Angelman syndrome and infantile spasms.^[1] It was also under development for the treatment of amyotrophic lateral sclerosis (ALS), anxiety disorders, autistic spectrum disorders, cognition disorders, multiple sclerosis, and stroke, but development for these indications was discontinued.^[1]